Ma, X. Rosa http://orcid.org/0000-0001-8297-4279
Prudencio, Mercedes http://orcid.org/0000-0002-4894-4858
Koike, Yuka http://orcid.org/0000-0002-5067-8579
Vatsavayai, Sarat C.
Kim, Garam http://orcid.org/0000-0001-5907-1127
Harbinski, Fred
Briner, Adam http://orcid.org/0000-0002-4760-5037
Rodriguez, Caitlin M.
Guo, Caiwei
Akiyama, Tetsuya http://orcid.org/0000-0002-8076-1242
Schmidt, H. Broder
Cummings, Beryl B.
Wyatt, David W.
Kurylo, Katherine
Miller, Georgiana
Mekhoubad, Shila
Sallee, Nathan
Mekonnen, Gemechu
Ganser, Laura
Rubien, Jack D. http://orcid.org/0000-0003-1203-0445
Jansen-West, Karen
Cook, Casey N.
Pickles, Sarah
Oskarsson, Björn http://orcid.org/0000-0002-1725-9866
Graff-Radford, Neill R.
Boeve, Bradley F. http://orcid.org/0000-0002-4153-8187
Knopman, David S. http://orcid.org/0000-0002-6544-066X
Petersen, Ronald C.
Dickson, Dennis W. http://orcid.org/0000-0001-7189-7917
Shorter, James
Myong, Sua
Green, Eric M. http://orcid.org/0000-0001-7874-9482
Seeley, William W.
Petrucelli, Leonard
Gitler, Aaron D. http://orcid.org/0000-0001-8603-1526
Article History
Received: 2 April 2021
Accepted: 13 January 2022
First Online: 23 February 2022
Competing interests
: A.D.G. is a scientific founder of Maze Therapeutics. X.R.M. served as a consultant for Maze Therapeutics. M.P. and L.P. serve as consultants for Target ALS. F.H., B.B.C., D.W.W., K.K., G. Miller, S. Mekhoubad, N.S. and E.G. are employees of Maze Therapeutics, which has filed a patent (63/171,522) on methods to modulate splicing of <i>UNC13A</i>.